Liquid Biopsy After Resection Of Pancreatic Adenocarcinoma And Its Relation To Oncological Outcomes. Systematic Review And Meta-Analysis
Pancreatic ductal adenocarcinoma (PDAC) is the seventh cause of cancer-related death worldwide and third place in Europe [1,2]. The actual 5-year survival rate is 12% [3]. This low survival rate is mainly due to late diagnosis, aggressive biology and resistance to current chemotherapy regimens [4 –7]. Only 20% are resectable at diagnosis; despite surgical resection, approximately 80% recurred. Furthermore, several factors may contribute to the recurrence of PDAC after resection, such as R1 status (
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Laura Vidal, Elizabeth Pando, Laia Blanco, Carles Fabregat – Franco, Florian Castet, Alexandre Sierra, Teresa Macarulla, Joaquim Balsells, Ramón Charco, Ana Vivancos Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Adenocarcinoma | Biology | Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Study